MedPath

Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-

Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
First Posted Date
2008-03-20
Last Posted Date
2011-06-28
Lead Sponsor
Japan Clinical Cancer Research Organization
Target Recruit Count
300
Registration Number
NCT00639327
Locations
🇯🇵

Hirosahi University Graduate School of Medicine, Hirosaki, Aomori, Japan

🇯🇵

Fukuyama City Hospital, Fukuyama, Hiroshima, Japan

🇯🇵

Asahikawa Medical College Hospital, Asahikawa, Hokkaido, Japan

and more 83 locations

Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2008-03-05
Last Posted Date
2020-11-09
Lead Sponsor
Federation Francophone de Cancerologie Digestive
Target Recruit Count
86
Registration Number
NCT00628810
Locations
🇫🇷

Hopital Ambroise Pare, Boulogne-Billancourt, France

🇫🇷

Hopital Du Bocage, Dijon, France

🇫🇷

Centre Hospitalier Departemental, La Roche Sur Yon, France

and more 29 locations

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

Phase 2
Completed
Conditions
Breast Cancer
Metastatic Cancer
Interventions
First Posted Date
2008-02-18
Last Posted Date
2018-04-20
Lead Sponsor
University of California, San Francisco
Target Recruit Count
30
Registration Number
NCT00617539
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2
Conditions
Lung Cancer
First Posted Date
2008-02-15
Last Posted Date
2009-02-09
Lead Sponsor
Yonsei University
Target Recruit Count
41
Registration Number
NCT00616785
Locations
🇰🇷

Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of

Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV

Phase 2
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2008-02-14
Last Posted Date
2011-05-23
Lead Sponsor
Hellenic Oncology Research Group
Target Recruit Count
124
Registration Number
NCT00614965
Locations
🇬🇷

Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece

🇬🇷

IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Phase 2
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
Biological: dalotuzumab
Biological: cetuximab
Drug: irinotecan hydrochloride
Drug: placebo
First Posted Date
2008-02-13
Last Posted Date
2018-08-08
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
558
Registration Number
NCT00614393

Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer

Phase 1
Completed
Conditions
Esophageal Cancer
Interventions
First Posted Date
2008-01-28
Last Posted Date
2013-03-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
27
Registration Number
NCT00601692
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas

Phase 2
Completed
Conditions
Glioblastoma
Gliosarcoma
Brain Tumor
Interventions
Drug: Avastin
Drug: Temozolomide
Radiation: Radiation Therapy (XRT)
Drug: Irinotecan
First Posted Date
2008-01-18
Last Posted Date
2014-05-07
Lead Sponsor
Duke University
Target Recruit Count
125
Registration Number
NCT00597402
Locations
🇺🇸

Duke University Health System, Durham, North Carolina, United States

Phase I/II Combination With Irinotecan- Erbitux

Phase 1
Completed
Conditions
Metastatic Colorectal Cancer (MCRC)
Interventions
First Posted Date
2008-01-16
Last Posted Date
2015-11-04
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
38
Registration Number
NCT00594984
Locations
🇺🇸

Usc/Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States

🇺🇸

Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Washington University, Saint Louis, Missouri, United States

and more 2 locations

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

Phase 2
Completed
Conditions
Esophageal Carcinoma
Interventions
Drug: Cisplatin
Drug: Irinotecan
Radiation: External Beam Radiation Therapy
First Posted Date
2008-01-10
Last Posted Date
2016-01-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
61
Registration Number
NCT00590031
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath